Biogen (BIIB) EPS (Weighted Average and Diluted) (2009 - 2026)

Biogen's EPS (Weighted Average and Diluted) history runs 18 years deep, the most recent figure standing at $2.15 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 31.1% year-over-year to $2.15; the TTM figure through Mar 2026 stood at $9.3 (down 8.19% YoY), while the FY2025 annual figure was $8.79, down 21.38% from the prior year.
• EPS (Weighted Average and Diluted) was $2.15 for Q1 2026 at Biogen, up from -$0.35 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $7.84 in Q3 2022 to a low of -$0.47 in Q3 2023.
• Historically, EPS (Weighted Average and Diluted) has averaged $3.0 across 5 years, with a median of $2.67 in 2023.
• The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) jumped 665.96% in 2024, then sank 119.13% in 2025.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $3.8 in 2022, then slumped by 55.0% to $1.71 in 2023, then advanced by 7.02% to $1.83 in 2024, then tumbled by 119.13% to -$0.35 in 2025, then soared by 714.29% to $2.15 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $2.15 (Q1 2026), -$0.35 (Q4 2025), and $3.17 (Q3 2025), per Business Quant data.